Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917527 | 1.00 | SIGMAR1 (0.47) | SIGMAR1HRH3KDM4EALDH1A1MEN1 | |
| SCHEMBL9917526 | 1.00 | SIGMAR1 (0.47) | SIGMAR1HRH3KDM4EALDH1A1MEN1 | |
| SCHEMBL9917519 | 0.90 | HRH3 (0.50) | SIGMAR1HRH3KDM4EKCNH2 | |
| SCHEMBL13186712 | 0.89 | HRH3 (0.47) | SIGMAR1HRH3KDM4EALDH1A1MEN1 | |
| SCHEMBL13186708 | 0.89 | HRH3 (0.47) | SIGMAR1HRH3KDM4EALDH1A1MEN1 | |
| SCHEMBL9917475 | 0.88 | CCR5 (0.43) | SIGMAR1HRH3 | |
| SCHEMBL13186715 | 0.86 | CNR2 (0.38) | SIGMAR1HRH3KDM4EALDH1A1MEN1 | |
| SCHEMBL16418023 | 0.85 | HRH3 (0.45) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9917534 | 0.84 | SIGMAR1 (0.55) | SIGMAR1HRH3KDM4EALDH1A1MEN1 | |
| SCHEMBL9917472 | 0.82 | HRH3 (0.55) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940730-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | SIGMAR1 2333/4885HRH3 4193/4885KDM4E 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.